ライフサイエンスコーパス: antihypertensive drug

1 ic blood pressure <140/90 mmHg and no use of antihypertensive drugs).

2 d within 48 h of stroke and the last dose of antihypertensive drug.

3 patients who had been prescribed at least 1 antihypertensive drug.

4 -dose HCTZ monotherapy is not an appropriate antihypertensive drug.

5 angiotensin system blocker and an additional antihypertensive drug.

6 ontinue (n=379) or stop (n=384) pre-existing antihypertensive drugs.

7 ned their treatment goals with three or more antihypertensive drugs.

8 that NPPA may modulate the efficacy of some antihypertensive drugs.

9 ir products, and may guide the design of new antihypertensive drugs.

10 ttenuated but not eliminated by adding other antihypertensive drugs.

11 may offer new targets for the development of antihypertensive drugs.

12 hypertensive patients' response to different antihypertensive drugs.

13 s expected most (89%) are requiring multiple antihypertensive drugs.

14 e patients receiving ACE inhibitors or other antihypertensive drugs.

15 ypertensive agents compared with nonusers of antihypertensive drugs.

16 n, we selected a stratified random sample of antihypertensive drugs.

17 ure and are targets for clinically effective antihypertensive drugs.

18 eated using standard country guideline-based antihypertensive drugs.

19 ti-inflammatory, analgesic, neurological and antihypertensive drugs.

20 the outcome risk associated with exposure to antihypertensive drugs.

21 y the proportion of the follow-up covered by antihypertensive drugs.

22 zations recommend lifestyle modification and antihypertensive drugs.

23 ng treatment goals and choice and dosages of antihypertensive drugs.

24 a blood pressure of >=140/90 mm Hg or taking antihypertensive drugs.

25 stigate the potential sex-specific impact of antihypertensive drugs.

26 hs, despite a similar treatment intensity of antihypertensive drugs.

27 among older adults that may be attributed to antihypertensive drugs.

28 blood pressure control requires four or more antihypertensive drugs.

29 right after generic commercialization for 3 antihypertensive drugs.

30 s imaging-based high-throughput screening of antihypertensive drugs.

31 stal nephron is a target of highly effective antihypertensive drugs.

32 an attractive target for the development of antihypertensive drugs.

33 tia in a heterogeneous group of new users of antihypertensive drugs.

34 s, and 25% (1,740/7,008) were not prescribed antihypertensive drugs.

35 icated, 3,194 anticoagulant drugs, and 7,008 antihypertensive drugs.

36 sure >/=90 mmHg, and/or self-reported use of antihypertensive drugs.

37 lemented by the sequential addition of other antihypertensive drugs.

38 the result of control with aggressive use of antihypertensive drugs.

39 1 +/- 16 mmHg despite the use of 5.6 +/- 1.3 antihypertensive drugs.

40 7%, P=0.001) at 2 years while requiring less antihypertensive drugs.

41 sion are also associated with BP response to antihypertensive drugs.

42 mended for most patients before the start of antihypertensive drugs.

43 Trained interviewers recorded use of antihypertensive drugs.

44 d 24-h BP with HCTZ in comparison with other antihypertensive drugs.

45 n 1992, of the 10 most frequently prescribed antihypertensive drugs, 3 were calcium antagonists, 3 we

46 Even though 67.3% of patients were on antihypertensive drugs, 46.0% of all patients had at lea

47 t calcium-channel blockers differ from other antihypertensive drugs, a meta-analysis that included al

48 or native AnCE and in complex with six known antihypertensive drugs, a novel C-domain sACE specific i

49 bial properties, is evaluated as a potential antihypertensive drug acting on this axis.

50 Difference in the change of number of antihypertensive drugs after 2 years was a secondary end

51 scriptions and >= 180 defined daily doses of antihypertensive drugs (AHTs) within a year, during a me

52 ssure-lowering effect for any combination of antihypertensive drugs, allowing their efficacy to be cl

53 ge or older who were receiving more than one antihypertensive drug and had a systolic blood pressure

54 Even with multiple antihypertensive drugs and aggressive lifestyle modifica

55 We assessed the association between antihypertensive drugs and cancer risk in a comprehensiv

56 management therefore often requires multiple antihypertensive drugs and concurrent treatment of dysli

57 identified factors, such as prescriptions of antihypertensive drugs and frequency of healthcare visit

58 Eligible patients were on >/=3 antihypertensive drugs and had a baseline systolic blood

59 essential mechanism for clearing many common antihypertensive drugs and other metabolites and toxins.

60 nuary, 2005, for randomised trials assessing antihypertensive drugs and progression of renal disease.

61 on was found between use of other individual antihypertensive drugs and risk of psoriasis.

62 ex, year, propensity score, and use of other antihypertensive drugs and statins, DiCCB use was associ

63 Novel factors associated with VTDR include antihypertensive drugs and statins.

64 le to those seen with other major classes of antihypertensive drugs and that these falls are associat

65 ssociation between use of ACEI/ARBs vs other antihypertensive drugs and the incidence rate of a COVID

66 tify the blood pressure-lowering efficacy of antihypertensive drugs and their combinations from the f

67 fficult to control, often requiring multiple antihypertensive drugs and treatment of other risk facto

68 or long-acting calcium antagonists or other antihypertensive drugs and who were followed up for at l

69 future randomized trials comparing different antihypertensive drugs and, most important, the selectio

70 Lipid-lowering therapy, antihypertensive drugs, and anticalcific therapy have be

71 on the systolic blood pressure and number of antihypertensive drugs, and applied retrospectively to a

72 as the use of other antihypertensive and non-antihypertensive drugs, and case patients had a worse cl

73 lar events and in accounting for benefits of antihypertensive drugs, and draws attention to clinical

74 ory of diabetes mellitus, total cholesterol, antihypertensive drugs, and lipid-lowering drugs.

75 Most patients did not change the number of antihypertensive drugs, and there was no evidence of dif

76 k of vascular events and for the benefits of antihypertensive drugs, and this notion has come to unde

77 disease, diabetes, lung disease, and use of antihypertensive drugs; and other types of physical acti

78 In addition to inadequate prescription of antihypertensive drugs, another confounder is poor diagn

79 ates for beta3- and beta2-receptor agonists, antihypertensive drugs, antiviral agents, melatonin rece

80 Most comparisons of antihypertensive drugs are undertaken in parallel groups

81 To achieve therapy goals, multiple antihypertensive drugs are usually needed.

82 Although antihypertensive drugs are widely available, in many pat

83 m antagonists are inferior to other types of antihypertensive drugs as first-line agents in reducing

84 ent submitted to medical therapy was free of antihypertensive drugs at 12 months.

85 HTN trial, the prevalence of nonadherence to antihypertensive drugs at 6 months was high ( approximat

86 lone, and 29,096 infants with no exposure to antihypertensive drugs at any time during gestation.

87 atrial fibrillation or taking rate-limiting antihypertensive drugs at baseline were excluded.

88 last trial visit, the mean (+/-SD) number of antihypertensive drugs being used decreased from 2.6+/-0

89 points included the changes in the number of antihypertensive drugs being used from baseline to the l

90 , Italy, aged >=65 years, who started taking antihypertensive drugs between 2009 and 2012.

91 e-pill combinations (SPCs) of three low-dose antihypertensive drugs can improve hypertension control

92 Lipid-lowering, anticoagulant, and antihypertensive drugs can prevent strokes, but may be u

93 tive was to quantify the association between antihypertensive drug class and adherence in clinical se

94 no associations were identified between any antihypertensive drug class and risk of any cancer (HR 0

95 When assessing each antihypertensive drug class individually, the largest ef

96 tal of 168 612 patients, with 42 153 in each antihypertensive drug class.

97 ing indications for the initial use of other antihypertensive drug classes (angiotensin-converting en

98 Patients treated with 1 of 4 antihypertensive drug classes (beta-blockers, ARBs, angi

99 of epilepsy and ARBs compared with all other antihypertensive drug classes as a group.

100 In adults with hypertension, how do various antihypertensive drug classes differ in their benefits a

101 Whether antihypertensive drug classes differentially affect clin

102 We aimed to determine whether antihypertensive drug classes differentially affect micr

103 Genetic proxies for the effect of antihypertensive drug classes were identified as variant

104 etic therapy but not present for other major antihypertensive drug classes, and did not differ substa

105 Compared with the other first-line antihypertensive drug classes, beta blockers are signifi

106 ressure despite treatment with at least four antihypertensive drug classes, including an MRA.

107 ociated with ARB therapy compared with other antihypertensive drug classes.

108 or uncontrolled intraocular pressure despite antihypertensive drugs combined to cyclophotocoagulation

109 ring of blood pressure and self-titration of antihypertensive drugs, combined with telemonitoring of

110 compared with placebo or no treatment, more antihypertensive drugs compared with fewer antihypertens

111 Of all 1-way sensitivity analyses, high antihypertensive drug cost and lower treatment efficacy

112 The findings suggest antihypertensive drugs could be used as a novel approach

113 ent parameters as indexes to predict how the antihypertensive drugs could influence muscle function.

114 The exclusion of women on antihypertensive drugs did not alter the results.

115 ly and non-adjustment for lipid-lowering and antihypertensive drugs did not introduce major biases in

116 Continuation of antihypertensive drugs did not reduce 2-week death or de

117 ecline in pCBF, whereas patients using other antihypertensive drugs did show a decline in pCBF.

118 Antihypertensive drugs differ in their effects on left a

119 stic sensitivity analyses explored ranges of antihypertensive drug effectiveness and costs, monitorin

120 Spironolactone is an effective antihypertensive drug, especially for patients with resi

121 have an influence: 41.7% of patients taking antihypertensive drugs experienced a severe reaction com

122 ts, no dose reductions, and no more than two antihypertensive drugs for 2 consecutive weeks were stra

123 tion to either continue or stop pre-existing antihypertensive drugs for 2 weeks.

124 nce of baseline comorbidities, and trials of antihypertensive drugs for indications other than hypert

125 ports the indication for selected classes of antihypertensive drugs for the prevention of diabetes, w

126 The fixed-dose combination of any two antihypertensive drugs from different drug classes is ty

127 ic strategy in which the clinically licensed antihypertensive drug guanabenz (Wytensin) activates a s

128 Here, we investigate how the FDA-approved antihypertensive drug, guanabenz, which has a favorable

129 els found that participants who received any antihypertensive drugs had a 29% increased hazard rate o

130 patients' age in regression analysis, taking antihypertensive drugs had no effect on symptom severity

131 The risk of cancer from antihypertensive drugs has been much debated, with a rec

132 In contrast, few of the antihypertensive drugs have been found to be carcinogeni

133 Antihypertensive drugs have disparate effects on LV mass

134 Randomization to 1 of 6 antihypertensive drugs: hydrochlorothiazide, atenolol, c

135 spite the availability of effective and safe antihypertensive drugs, hypertension and its concomitant

136 hageal reflux disease drugs, diabetes drugs, antihypertensive drugs, hypnotic drugs approved for the

137 ry modification, exercise, antioxidants, and antihypertensive drugs improve endothelial dysfunction i

138 Labetalol and lisinopril are effective antihypertensive drugs in acute stroke that do not incre

139 s have explored the renal effects of various antihypertensive drugs in animal models and humans, rece

140 od for the simultaneous quantification of 18 antihypertensive drugs in human plasma.

141 afety of continuing or stopping pre-existing antihypertensive drugs in patients who had recently had

142 ore associated with heart failure than other antihypertensive drugs in patients.

143 Losartan is exceptional amongst antihypertensive drugs in possessing mild uricosuric pro

144 ting enzyme inhibitors are superior to other antihypertensive drugs in reducing the risk for acute my

145 ences in the proportion with prescription of antihypertensive drugs in the intervention vs control gr

146 Unexplained differences between classes of antihypertensive drugs in their effectiveness in prevent

147 ossover rotation of the four main classes of antihypertensive drugs, in untreated young hypertensive

148 0 mm Hg, despite adherence to >/=3 full-dose antihypertensive drugs including a diuretic agent or >/=

149 mm Hg if diabetes) despite treatment with 3 antihypertensive drugs including a diuretic.

150 iate pharmacologic treatment with at least 3 antihypertensive drugs, including a diuretic agent.

151 ast 160 mm Hg and were taking at least three antihypertensive drugs, including a diuretic, at the opt

152 re (BP) >/=140/90 mm Hg (with at least three antihypertensive drugs, including a diuretic, in adequat

153 dised background therapy consisting of three antihypertensive drugs, including a diuretic.

154 AT(1) R blockers, clinically used as antihypertensive drugs, inhibit both signaling pathways,

155 e been demonstrated by quickly accessing the antihypertensive drug irbesartan (2).

156 iption of lipid-lowering, anticoagulant, and antihypertensive drugs is important to reduce the incide

157 e on the benefits and risks of discontinuing antihypertensive drugs is limited.

158 In the absence of new antihypertensive drugs, it is important that healthcare

159 ACE (both in the presence and absence of the antihypertensive drug lisinopril) in order to aid the un

160 bined measure of systolic blood pressure and antihypertensive drug load, was used as a measure of pre

161 All antihypertensive drugs lower blood pressure (by definiti

162 Antihypertensive drugs may differ in their ability to re

163 ese preclinical studies suggest that certain antihypertensive drugs may have AD-modifying activity an

164 gain after smoking cessation and the use of antihypertensive drugs may have counterbalanced the bene

165 These observations suggest not only that antihypertensive drugs may have important mechanisms of

166 lleviated, blood pressure lowering with many antihypertensive drugs may not be able to alleviate left

167 irms UNAGI's predictions that nifedipine, an antihypertensive drug, may have anti-fibrotic effects on

168 The efficacy of antihypertensive drugs newer than diuretics and beta-blo

169 tigational drug was compared with the common antihypertensive drug nifedipine, which has 4.5-fold sel

170 eve recommended blood pressure levels on >=3 antihypertensive drugs of different classes.

171 Patients were treated with 5.1 +/- 1.4 antihypertensive drugs on average.

172 The effect of antihypertensive drugs on cardiovascular events in patie

173 50% of patients with acute stroke are taking antihypertensive drugs on hospital admission.

174 The effect of different classes of antihypertensive drugs on incident diabetes mellitus is

175 the effects of calcium antagonists and other antihypertensive drugs on major cardiovascular events.

176 re can account for differences in effects of antihypertensive drugs on risk of stroke independently o

177 reached, have been neglected, and effects of antihypertensive drugs on such measures are largely unkn

178 ly, we review the known effects of available antihypertensive drugs on the arterial wall and indicate

179 ifferential effects of five major classes of antihypertensive drugs on the risk of new-onset type 2 d

180 Hg) who were randomly assigned to an active (antihypertensive drug or more intensive regimen) or cont

181 stolic hypertension while taking two or more antihypertensive drugs or chronic kidney disease to medi

182 ng doxazosin, treatment assignment to either antihypertensive drugs or pravastatin versus usual care

183 VTDR, we also found novel associations with antihypertensive drugs (OR: 0.18; 95% CI: 0.06-0.61) and

184 e antihypertensive drugs compared with fewer antihypertensive drugs, or higher blood pressure targets

185 Among the 3648 patients receiving antihypertensive drugs other than ACE inhibitors (calciu

186 Therefore, in addition to their use as antihypertensive drugs, our results suggest that thiazid

187 the FDA Adverse Event Reporting System; 134 antihypertensive drugs out of 1131 drugs were filtered a

188 , hypertension status, and use and dosing of antihypertensive drugs over the course of the trial.

189 .043; aOR = 1.61) and the intake of multiple antihypertensive drugs (p < 0.001; aOR = 3.96) showed a

190 (p=0.002), and -17.9 cm/s in never users of antihypertensive drugs (p=0.001).

191 /s in continuous/intermittent users of other antihypertensive drugs (p=0.002), and -17.9 cm/s in neve

192 kg in continuous/intermittent users of other antihypertensive drugs (p=0.016) and with -3.9 kg in tho

193 al outcomes) based on blood pressure, use of antihypertensive drugs, plasma potassium and aldosterone

194 We found that the antihypertensive drug Prazosin inhibits endocytic sortin

195 ic was used to improve the solubility of the antihypertensive drug prazosin without affecting its bio

196 lacebo group received placebo and any active antihypertensive drugs prescribed by patient's private p

197 or older who had hypertension and at least 1 antihypertensive drug prescription.

198 sure lowering by lifestyle modifications and antihypertensive drugs reduce cardiovascular (CV) morbid

199 and death, and lowering blood pressure with antihypertensive drugs reduces target organ damage and p

200 with guanabenz acetate (GA), an FDA-approved antihypertensive drug, reduces the size and number of nu

201 The SHEP antihypertensive drug regimen lowered BP of both diabeti

202 Patients' adherence to antihypertensive drug regimens is a complex but importan

203 Recommended low-salt diet and triple antihypertensive drug regimens that include a diuretic,

204 lood pressure, adding meaningful efficacy to antihypertensive drug regimens.

205 re, understanding the therapeutic effects of antihypertensive drugs related to apoptosis may identify

206 Use of antihypertensive drugs remained similar in both study ar

207 nsin type 1 receptor antagonist losartan, an antihypertensive drug, repurposed for the treatment of P

208 with the antichorea drug tetrabenazine, the antihypertensive drug reserpine or the substrate seroton

209 (+), the psychostimulant amphetamine and the antihypertensive drug reserpine.

210 encing data to identify molecular markers of antihypertensive drug response.

211 ly and non-adjustment for lipid-lowering and antihypertensive drugs resulted in marginal changes in O

212 Taking antihypertensive drugs seemed to have an influence: 41.7

213 tion of the effects of five major classes of antihypertensive drugs showed that in comparison to plac

214 rugs, gastroesophageal reflux disease drugs, antihypertensive drugs, sleep aids, attention-deficit/hy

215 noic acid and Idoxuridine and reduced by the antihypertensive drug Spironolactone.

216 r frequently prescribed drug classes, namely antihypertensive drugs, statins, selective serotonin reu

217 -related deaths with any individual class of antihypertensive drugs studied.

218 vailable data on the renal outcomes of other antihypertensive drugs such as calcium antagonists have

219 Expression levels of antihypertensive drug target genes as proxies for drug e

220 entified as influencing maternal SBP via the antihypertensive drug target instruments.

221 between genetically proxied inhibition of 3 antihypertensive drug targets and risk of 4 common cance

222 ns between genetically-proxied inhibition of antihypertensive drug targets and risk of common cancer

223 urally occurring variation in genes encoding antihypertensive drug targets can be used as proxies for

224 rnal genetic variants for SBP that influence antihypertensive drug targets had potential causal relat

225 Novel genetic instruments for maternal antihypertensive drug targets that act via systolic bloo

226 lity and contractility and are implicated as antihypertensive drug targets.

227 mm Hg, [-9.47 to -0.79]) as their additional antihypertensive drug than in those receiving a thiazide

228 ence was higher among participants receiving antihypertensive drugs than those who did not.

229 the fibrosis using losartan, an FDA-approved antihypertensive drug that blocks fibrotic and inflammat

230 nest treatment, minoxidil, was originally an antihypertensive drug that promoted unwanted hair.

231 by amlodipine and verapamil, are widely used antihypertensive drugs that also have antiinflammatory a

232 such as verapamil are a widely used class of antihypertensive drugs that block L-type calcium channel

233 uretics are structurally distinct first-line antihypertensive drugs that target the sodium-chloride c

234 nd was added to a mean of 2.0 (SD 0.3) other antihypertensive drugs; the mean starting and final dose

235 or the first time to guide the initiation of antihypertensive drug therapy and recommended calculatio

236 of age who were free of CHD and were not on antihypertensive drug therapy at baseline.

237 In this population, specific antihypertensive drug therapy had little impact on the r

238 ere grouped according to recommendations for antihypertensive drug therapy in the 2017 ACC/AHA guidel

239 SBP >=160 mm Hg or DBP >=100 mm Hg or taking antihypertensive drug therapy were excluded from the stu

240 ment, to equitably improve the initiation of antihypertensive drug therapy, blood pressure control, a

241 Stepped-care antihypertensive drug therapy, in which the step 1 drug

242 rching paradigm for risk-based initiation of antihypertensive drug therapy, it updated the recommende

243 After excluding subjects receiving antihypertensive drug therapy, up to 30 years of data on

244 pressure can be controlled through existing antihypertensive drug therapy.

245 h no clinical evidence of CHD and not taking antihypertensive drug therapy.

246 and angiotensin blockers as cornerstones of antihypertensive drug therapy.

247 st, is the first agent from a novel class of antihypertensive drug to be licensed since 2007 and exem

248 was not being treated or was taking only one antihypertensive drug) to receive a daily regimen of 5 m

249 consisted of withdrawal of antidiabetes and antihypertensive drugs, total diet replacement (825-853

250 ion comprised withdrawal of antidiabetic and antihypertensive drugs, total diet replacement (825-853

251 duration >=6 months; control: less intensive antihypertensive drug treatment (higher blood pressure g

252 vention: randomized trials of more intensive antihypertensive drug treatment (lower blood pressure go

253 pants and for men receiving or not receiving antihypertensive drug treatment and were controlled for

254 ow-up duration between 4 weeks and 26 weeks, antihypertensive drug treatment fixed in all participant

255 the old fraction of the general population, antihypertensive drug treatment is associated with a low

256 This study sought to evaluate the effect of antihypertensive drug treatment on the risk of dementia

257 In this study, antihypertensive drug treatment reduced the incidence of

258 Simplified antihypertensive drug treatment such as single-pill comb

259 mized clinical trial testing the efficacy of antihypertensive drug treatment to reduce the risk of st

260 m Hg or DBP >/=90 mm Hg or the initiation of antihypertensive drug treatment, occurred in 228 men (22

261 our groups according to type and duration of antihypertensive drug treatment.

262 of a higher treatment rate and more intense antihypertensive drug treatment.

263 rdiovascular history, and lipid-lowering and antihypertensive drug treatments.

264 = 6); or SP combined with nonspecific triple antihypertensive drugs (TRX; reserpine, hydralazine, and

265 2 mm Hg, despite medication with 5.4 +/- 1.4 antihypertensive drugs) underwent RDN.

266 with randomisation stratified by additional antihypertensive drug use and insulin use at baseline, i

267 Multiple antihypertensive drug use increased from 29.1% to 35.8%

268 nd similar diuretics, and the association of antihypertensive drug use with new-onset diabetes and it

269 tudy, we compared changes in blood pressure, antihypertensive drug use, and safety up to 36 months in

270 Advancing age, male sex, antihypertensive drug use, higher body mass index, previ

271 Hypertension was defined as predonation antihypertensive drug use.

272 We aimed at evaluating racial differences in antihypertensive drug utilization patterns and blood pre

273 als that used a specific class or classes of antihypertensive drugs versus placebo or other classes o

274 f controls; ACEI/ARB use compared with other antihypertensive drugs was not significantly associated

275 90] mm Hg; p > 0.01) but the requirement for antihypertensive drugs was unchanged.

276 This cohort study found that antihypertensive drugs were associated with a small incr

277 ribed when lipid-lowering, anticoagulant, or antihypertensive drugs were clinically indicated but wer

278 Patients aged over 18 years who were taking antihypertensive drugs were enrolled within 48 h of stro

279 igible for lipid-lowering, anticoagulant, or antihypertensive drugs were not prescribed them prior to

280 HI was 40.4 (SD, 18.9) and an average of 3.8 antihypertensive drugs were taken per patient.

281 al side effects and repurposing potential of antihypertensive drugs, which are among the most commonl

282 Other antihypertensive drugs, while not tested in large trials

283 Multiple antihypertensive drugs will be required in the vast majo

284 ect of different durations of treatment with antihypertensive drugs with anticholinergic properties (

285 tudinal association of hypertension, BP, and antihypertensive drugs with change in parenchymal cerebr

286 y and mortality, despite the availability of antihypertensive drugs with different targets and mechan

287 The association of antihypertensive drugs with incident diabetes is therefo

288 ss than 170 mm Hg, while taking one to three antihypertensive drugs with stable doses for at least 6

289 ypertension receiving between zero and three antihypertensive drugs, with a screening systolic blood

290 erapies consisting of a statin and 1 or more antihypertensive drugs, with or without aspirin, can red

291 Exposure date by first prescription for an antihypertensive drug within each drug class.

292 prescription of lipid-lowering drugs but not antihypertensive drugs within the following 465 days.

293 HCTZ is the most commonly prescribed antihypertensive drug worldwide.

294 arisons of ACE inhibitors or ARBs with other antihypertensive drugs yielded a relative risk of 0.71 (